An Open-Label, Single-Dose, Parallel-Group Study to Compare the Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment With That in Matched Control Subjects With Relatively Normal Renal Function.

Trial Profile

An Open-Label, Single-Dose, Parallel-Group Study to Compare the Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment With That in Matched Control Subjects With Relatively Normal Renal Function.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2014

At a glance

  • Drugs Tasimelteon (Primary)
  • Indications Circadian rhythm sleep disorders; Insomnia; Major depressive disorder
  • Focus Pharmacokinetics
  • Most Recent Events

    • 25 Jun 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
    • 25 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Feb 2012 Additional lead trial investigator (Kambiz Farbakhsh) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top